A citation-based method for searching scientific literature

B N Atkinson, S C Bell, M De Vivo, L R Kowalski, S M Lechner, V I Ognyanov, C S Tham, C Tsai, J Jia, D Ashton, M A Klitenick. Mol Pharmacol 2001
Times Cited: 145



Guochuan Tsai, Rebecca J Ralph-Williams, Marzia Martina, Richard Bergeron, Joanne Berger-Sweeney, Kevin S Dunham, Zhichun Jiang, S Barak Caine, Joseph T Coyle. Proc Natl Acad Sci U S A 2004
Times Cited: 155




List of shared articles



Times cited

D-Serine and Glycine Differentially Control Neurotransmission during Visual Cortex Critical Period.
Claire N J Meunier, Glenn Dallérac, Nicolas Le Roux, Silvia Sacchi, Grégoire Levasseur, Muriel Amar, Loredano Pollegioni, Jean-Pierre Mothet, Philippe Fossier. PLoS One 2016
22


Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.
Frank S Menniti, Craig W Lindsley, P Jeffrey Conn, Jayvardhan Pandit, Panayiotis Zagouras, Robert A Volkmann. Curr Top Med Chem 2013
60


Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery.
Andra Mihali, Shreya Subramani, Genevieve Kaunitz, Stephen Rayport, Inna Gaisler-Salomon. Expert Rev Neurother 2012
13



SLC6 neurotransmitter transporters: structure, function, and regulation.
Anders S Kristensen, Jacob Andersen, Trine N Jørgensen, Lena Sørensen, Jacob Eriksen, Claus J Loland, Kristian Strømgaard, Ulrik Gether. Pharmacol Rev 2011
478

Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors.
Scott E Wolkenberg, Cyrille Sur. Curr Top Med Chem 2010
29


Altered mnemonic functions and resistance to N-METHYL-d-Aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1.
P Singer, B K Yee, J Feldon, T Iwasato, S Itohara, T Grampp, G Prenosil, D Benke, H Möhler, D Boison. Neuroscience 2009
19

Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain.
Toshihiro Dohi, Katsuya Morita, Tomoya Kitayama, Naoyo Motoyama, Norimitsu Morioka. Pharmacol Ther 2009
76



Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
Kenneth W Perry, Julie F Falcone, Matthew J Fell, John W Ryder, Hong Yu, Patrick L Love, Jason Katner, Kimberly D Gordon, Mark R Wade, Teresa Man,[...]. Neuropharmacology 2008
70


Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.
Thomas M Bridges, Richard Williams, Craig W Lindsley. Curr Opin Mol Ther 2008
38